Clinical and immunological changes in patients with active moderate-to-severe Graves ̕ orbitopathy treated with very low-dose rituximab.
CONCLUSIONS: A single very low-dose of rituximab appears to be very well tolerated and effective enough to reduce clinical activity in active moderate-to-severe GO patients without impending DON.
PMID: 28660988 [PubMed - as supplied by publisher]
Source: Endokrynologia Polska - Category: Endocrinology Authors: Karasek D, Cibickova L, Karhanova M, Kalitova J, Schovanek J, Frysak Z Tags: Endokrynol Pol Source Type: research
More News: Allergy & Immunology | Brain | Endocrinology | Hormones | Laboratory Medicine | Neurology | Rituxan | Study | Thyroid | Women